Novo partners with Anthropic to speed up drug development with Claude

Sept 16 (Reuters) - Novo ‌Nordisk has ​partnered ​with Anthropic to use the AI giant's Claude models to speed up discovery ‌and development of new medicines, the companies said ⁠on Wednesday.

Here are more details:

• The Danish drugmaker will ‌initially test Anthropic models ‌and Claude Science in its research and development workflows, and address scientific problems where their ​joint capabilities can have the greatest impact, they said.

• "But beyond this, AI tools can also ⁠offer completely new scientific opportunities and aid reasoning and understanding of ​human biology and drug mechanics," Novo CEO Mike Doustdar said.

• Drugmakers are increasingly turning ​to artificial intelligence to accelerate ‌R&D and improve efficiency across their pipelines.

• The Wegovy maker will also ⁠use Anthropic's frontier models to strengthen AI-driven software development.

• "By giving leading researchers access to safe, capable, and trusted ⁠frontier models, we can shorten research timelines, improve outcomes, ​and discover medicines and treatments that significantly improve human life," said Dario Amodei, CEO of Anthropic.

• Meanwhile, AI industry ‌leaders are split over how fast companies should develop the increasingly powerful technology.

• ‌Novo already uses Claude to automate trial report ⁠generation, and trim ‌timelines for patient ​documentation creation from months to minutes.

(Reporting by Sriparna Roy in Bengaluru; Editing by Leroy ‌Leo)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• North Korea conducted test of upgraded rocket launcher system, KCNA says
• Wells Fargo's chief risk officer Derek Flowers to retire
• Trump to raise detainees with Xi, but other rights issues may not come up